Disease Domain | Count |
---|---|
Endocrinology and Metabolic Disease | 3 |
Neoplasms | 2 |
Nervous System Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 4 |
Synthetic peptide | 1 |
Target |
Mechanism ERα antagonists |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date27 Jan 2023 |
Target |
Mechanism ERs antagonists [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date20 May 2020 |
Target |
Mechanism CB antagonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date25 Jun 2018 |
Start Date01 Jun 2024 |
Sponsor / Collaborator Geisinger Ventures [+1] |
Start Date01 Jan 2023 |
Sponsor / Collaborator |
Start Date13 Apr 2022 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Alendronate Sodium | Osteoporosis, Postmenopausal More | Approved |
Abaloparatide ( PTH1R ) | Osteoporosis More | Approved |
Elacestrant hydrochloride ( ERα ) | Breast Cancer More | NDA/BLA |
RAD-140 ( AR ) | Breast Cancer More | Phase 1 |
SK-124 ( SIK1 x SIK2 x SIK3 ) | Osteoporosis More | Preclinical |